Edmonton, AB – BioMS Medical, a developer of treatments for multiple sclerosis, says it has appointed Dr Tony Verco, MBBCh, DA, to the newly created position of vice president of clinical and medical affairs.
“With our lead MS drug, MBP8298, poised to commence a pivotal trial, we have focused on assembling a world-class clinical development team, demonstrating our ongoing commitment to the advancement of this drug,” says Kevin Giese, the company’s president. “Dr Verco, having extensive experience in all phases of clinical trials and in a variety of therapeutic areas, will be a strong addition to this team.”
In his most recent position, Dr Verco was the medical director at Endpoint Research, where he was responsible for medical support and strategy for clients in a number of therapeutic areas, including multiple sclerosis. Prior to this, he was the medical director for AstraZeneca’s Clinical Pharmacology Unit in Nottingham, UK and has been a member of numerous drug safety monitoring boards. He earned a MBBCh degree from the University of the Witwatersrand in Johannesburg, South Africa, where he also earned his DA (Anaesthetics). He practiced clinical anaesthesia for five years before joining the pharmaceutical industry in 1996.